Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + leucovorin + fluorouracil + sintilimab + IBI305
- Development stage
- Unknown
- Lead developer
- Union Hospital of Huazhong University of Science and Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intra-arterial
01
Overview
This triple therapy regimen combines hepatic arterial infusion chemotherapy (HAIC) using the FOLFOX protocol (oxaliplatin, leucovorin, and fluorouracil) with systemic administration of the PD-1 inhibitor sintilimab and the bevacizumab biosimilar IBI305. Developed and studied at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this approach is designed for the first-line treatment of advanced (BCLC-C) unresectable hepatocellular carcinoma. The regimen leverages the high local drug concentration of HAIC to achieve tumor debulking and potential surgical conversion, while systemic sintilimab and IBI305 provide synergistic immune checkpoint blockade and anti-angiogenic effects to control extrahepatic spread and enhance the local therapeutic response.
- Brand names
- Byvasda
- Other names
- FOLFOX-HAIC + sintilimab + bevacizumab biosimilarHAIC-FOLFOX + sintilimab + IBI305HAIC + sintilimab + bevacizumabFOLFOXHAIC
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on oxaliplatin + leucovorin + fluorouracil + sintilimab + IBI305.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + leucovorin + fluorouracil + sintilimab + IBI305.